Literature DB >> 15943554

Deletions account for 17% of pathogenic germline alterations in MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer (HNPCC) families.

Monika Grabowski1, Yvonne Mueller-Koch, Eva Grasbon-Frodl, Udo Koehler, Gisela Keller, Holger Vogelsang, Wolfgang Dietmaier, Reinhard Kopp, Ulrike Siebers, Wolfgang Schmitt, Birgit Neitzel, Maria Gruber, Christa Doerner, Brigitte Kerker, Petra Ruemmele, Gabriele Henke, Elke Holinski-Feder.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is due to defects in DNA mismatch repair (MMR) genes MSH2, MLH1, MSH6, and to a lesser extent PMS2. Of 466 suspected HNPCC families, we defined 54 index patients with either tumors of high microsatellite instability (MSI-H) and/or loss of expression for either MLH1, MSH2, and/or MSH6, but without a detectable pathogenic point mutation in these genes. This study cohort was augmented to 64 patients by 10 mutation-negative index patients from Amsterdam families where no tumors were available. Deletion/duplication screening using the multiplex ligation-dependent probe amplification (MLPA) revealed 12 deletions in MSH2 and two deletions in MLH1. These deletions constitute 17% of pathogenic germline alterations but elucidate the susceptibility to HNPCC in only 22% of the mutation-negative study cohort, pointing towards other mutation mechanisms for an inherited inactivation of MLH1 or MSH2. We describe here four novel deletions. One novel and one known type of deletion were found for three and two unrelated families, respectively. MLPA analysis proved a reliable method for the detection of genomic deletions in MLH1 and MSH2; however, sequence variations in the ligation-probe binding site can mimic single exon deletions.

Entities:  

Mesh:

Year:  2005        PMID: 15943554     DOI: 10.1089/gte.2005.9.138

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  15 in total

1.  MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions.

Authors:  Jérémie H Lefevre; Chrystelle Colas; Florence Coulet; Carolina Bonilla; Najat Mourra; Jean-Francois Flejou; Emmanuel Tiret; Walter Bodmer; Florent Soubrier; Yann Parc
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

2.  Assessing the predictive accuracy of hMLH1 and hMSH2 mutation probability models.

Authors:  Kory W Jasperson; Katrina Lowstuter; Jeffrey N Weitzel
Journal:  J Genet Couns       Date:  2006-10       Impact factor: 2.537

3.  De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.

Authors:  Ajay Goel; Thuy-Phuong Nguyen; Hon-Chiu E Leung; Takeshi Nagasaka; Jennifer Rhees; Erin Hotchkiss; Mildred Arnold; Pia Banerji; Minoru Koi; Chau-To Kwok; Deborah Packham; Lara Lipton; C Richard Boland; Robyn L Ward; Megan P Hitchins
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

4.  Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.

Authors:  Monika Morak; Verena Steinke-Lange; Trisari Massdorf; Anna Benet-Pages; Melanie Locher; Andreas Laner; Katrin Kayser; Stefan Aretz; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2020-04       Impact factor: 2.375

5.  Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population.

Authors:  Mef Nilbert; Friedrik P Wikman; Thomas V O Hansen; Henrik B Krarup; Torben F Orntoft; Finn C Nielsen; Lone Sunde; Anne-Marie Gerdes; Dorthe Cruger; Susanne Timshel; Marie-Louise Bisgaard; Inge Bernstein; Henrik Okkels
Journal:  Fam Cancer       Date:  2008-06-20       Impact factor: 2.375

6.  Detection of allelic imbalance in MLH1 expression by pyrosequencing serves as a tool for the identification of germline defects in Lynch syndrome.

Authors:  Chau-To Kwok; Robyn L Ward; Nicholas J Hawkins; Megan P Hitchins
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

7.  Genetic diagnosis strategy of hereditary non-polyposis colorectal cancer.

Authors:  Jian-Qiu Sheng; Hong Zhang; Min Ji; Lei Fu; Hong Mu; Ming-Zhi Zhang; Ji-Sheng Huang; Min Han; Ai-Qin Li; Zhi Wei; Zi-Qin Sun; Zi-Tao Wu; Chang-Hong Xia; Shi-Rong Li
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

8.  Targeted deep-intronic sequencing in a cohort of unexplained cases of suspected Lynch syndrome.

Authors:  Dimitrij Frishman; Elke Holinski-Feder; Anke Marie Arnold; Monika Morak; Anna Benet-Pagès; Andreas Laner
Journal:  Eur J Hum Genet       Date:  2019-12-10       Impact factor: 4.246

9.  Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

Authors:  Katarina Zavodna; Tomas Krivulcik; Maria Gerykova Bujalkova; Tomas Slamka; David Martinicky; Denisa Ilencikova; Zdena Bartosova
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

10.  Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer.

Authors:  T Pal; M R Akbari; P Sun; J-H Lee; J Fulp; Z Thompson; D Coppola; S Nicosia; T A Sellers; J McLaughlin; H A Risch; B Rosen; P Shaw; J Schildkraut; S A Narod
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.